Managed Health Care launches new home infusion pharmacy

Managed Health Care Associates (MHA), a healthcare services and software company in Chicago, has released its new Home Infusion Pharmacy, which will help home infusion pharmacy customers compete in a value-based reimbursement market.

MHS partnered with Strategic Healthcare Programs (SHP), a data analytics provider based in Barbara, California, to develop the system, which provides access to benchmarking and real-time data to help treat patients. It responds to growing patient populations and alternate payment models.

"SHP is recognized as the absolute leader in the home health and hospice benchmarking and data analytics space, and this new home infusion solution will contain the same type of industry leading analytics,” said MHA President Michael J. Sicilian in a statement. “As the industry evolves in the new quality based reimbursement environment, home infusion providers are going to need very unique and detailed data to demonstrate their value. This new product will be an important component in showing that value.”

The product will be able to capture daily trends and insights from clinical, financial, demographic and utilization data.

"We are confident that these new reports and analytics will help Home Infusion providers to more effectively use their data to improve performance just as our other solutions do in the Home Health and Hospice markets,” said SHP President Rob Paulsson in a statement.

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup